Cost‐effectiveness analysis of primary treatments for localised prostate cancer: A population‐based Markov analysis using real‐world evidence.

MLA

Weng, Xiuhua, et al. “Cost‐effectiveness Analysis of Primary Treatments for Localised Prostate Cancer: A Population‐based Markov Analysis Using Real‐world Evidence.” European Journal of Cancer Care, vol. 31, no. 6, Nov. 2022, pp. 1–13. EBSCOhost, https://doi.org/10.1111/ecc.13740.

APA

Weng, X., Zhong, L., Xiang, P., Li, Y., Paciorek, A., Dong, L., Broering, J., Carroll, P. R., Sanda, M., & Wilson, L. (2022). Cost‐effectiveness analysis of primary treatments for localised prostate cancer: A population‐based Markov analysis using real‐world evidence. European Journal of Cancer Care, 31(6), 1–13. https://doi.org/10.1111/ecc.13740

Chicago

Weng, Xiuhua, Lixian Zhong, Pin Xiang, Yiyuan Li, Alan Paciorek, Liangliang Dong, Jeanette Broering, Peter R. Carroll, Martin Sanda, and Leslie Wilson. 2022. “Cost‐effectiveness Analysis of Primary Treatments for Localised Prostate Cancer: A Population‐based Markov Analysis Using Real‐world Evidence.” European Journal of Cancer Care 31 (6): 1–13. doi:10.1111/ecc.13740.